A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of Aflapin® in subjects with osteoarthritis of knee

International Journal of Medical Sciences

Volumn 8, Issue 7, 2011, Pages 615-622

  Vishal, Amar A ^a   Mishra, Artatrana ^a   Raychaudhuri, Siba P ^b  

^a Alluri Sitaramaraju Academy of Medical Sciences   (India)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Aflapin; Boswellia serrata; Clinical study; Osteoarthritis; Visual Analog Scale

Indexed keywords

AFLAPIN; ANTIRHEUMATIC AGENT; BOSWELLIA SERRATA EXTRACT; IBUPROFEN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BOSWELLIA; BOSWELLIA SERRATA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HUMAN; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN; PAIN ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

EID: 80054756699     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.8.615     Document Type: Article

References (32)

1. Felson DT: An update on the pathogenesis and epidemiology of osteoarthritis. Radiol Clin North Am 2004, 42:1-9.
2. Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM, Kington RS, Lane NE, Nevitt MC, Zhang Y, Sowers M, McAlindon T, Spector TD, Poole AR, Yanovski SZ, Ateshian G, Sharma L, Buckwalter JA, Brandt KD, Fries JF: Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med 2000, 133:635-646.
3. Karen WB, et al. Medical management of osteoarthritis. BMJ 2000; 321:936-940.
4. Bos SD, Slagboon PE, Meulenbelt I. New insights into osteoar-thritis: early developmental features of an aging related disease. Curr Opin Rheumatol. 2008; 20:553-559.
5. Pendleton A, Arden N, Dougados M, Doherty M, Bannwarth B, Bijlsma JW, Cluzeau F, Cooper C, Dieppe PA, Günther KP, Hauselmann HJ, Herrero-Beaumont G, Kaklamanis PM, Leeb B, Lequesne M, Lohmander S, Mazieres B, Mola EM, Pavelka K, Serni U, Swoboda B, Verbruggen AA, Weseloh G, Zimmer-mann-Gorska I: EULAR recommendations for the management of osteoarthritis: report of task force standing committee for International Clinical Studies including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2000, 59:936-944.
6. Singh G: Recent considerations in nonsteroidal an-ti-inflammatory drug gastropathy. Am J Med 1998, 105:31S-38S.
7. Griffin MR: Epidemiology of nonsteroidal anti-inflammatory drug associated gastrointestinal injury. Am J Med 1998, 104:23S-29S.
8. Wright JM: Double-edged sword of COX-2 selective NSAIDs. CMAJ 2002, 167:1131-1137.
9. Singh GB, Atal CK: Pharmacology of an extract of salai guggal ex-Boswellia serrata, a new non-steroidal anti-inflammatory agent. Agents Actions 1986, 18:407-412.
10. Ethan B, Heather B, Theresa DH, Ivo F, Sadaf H, Jens H, David S, Catherine U: Boswellia: An evidence-based systematic review by the natural standard research collaboration. J Herbal Phar-macother 2004, 4:63-83.
11. Safayhi H, Mack T, Sabieraj J, Anazodo MI, Subramanian LR, Ammon HPT: Boswellic acids: novel, specific, nonredox inhib-itors of 5-lipoxygenase. J Pharmacol Exp Ther 1992, 26:1143-1146.
12. Sailer ER, Subramanian LR, Rall B, Hoernlein RF, Ammon HPT, Safayhi H: Acetyl-11-keto-β-boswellic acid (AKBA): structure requirements or binding and 5-lipoxygenase inhibitory activity. Br J Pharmacol 1996, 117:615-618.
13. Joos S, Rosemann T, Szecsenyi J, Hahn EG, Willich SN, Brinkhaus B: Use of complementary and alternative medicine in Germany-a survey of subjects with inflammatory bowel dis-ease. BMC Complement Altern Med 2006, 6:19.
14. Anthoni C, Laukoetter MG, Rijcken E, Vowinkel T, Mennigen R, Muller S, Senninger N, Russell J, Jauch J, Bergmann J, Granger DN, Krieglstein CF: Mechanisms underlying the an-ti-inflammatory actions of boswellic acid derivatives in exper-imental colitis. Am J Physiol Gastrointest Liver Physiol 2006, 290:G1131-G1137.
15. Gupta I, Parihar A, Malhotra P, Gupta S, Ludtke R, Safayhi H, Ammon HP: Effects of gum resin of Boswellia serrata in subjects with chronic colitis. Planta Med 2001, 67:391-395.
16. Kimmatkar N, Thawani V, Hingorani L, Khiyani R: Efficacy and tolerability of Boswellia serrata extract in treatment of os-teoarthritis of knee: a randomized double blind placebo con-trolled trial. Phytomedicine 2003, 10:3-7.
17. Sengupta K, Kolla JN, Krishnaraju AV, Yalamanchili N, Rao CV, Golakoti T, Raychaudhuri S, Raychaudhuri SP. Cellular and molecular mechanisms of anti-inflammatory effect of Aflapin: a novel Boswellia serrata extract. Mol Cell Biochem. 2011, 354:189-197.
18. Krishnaraju AV, Sundararaju D, Vamsikrishna U, Suryachandra R, Machiraju G, Sengupta K, Trimurtulu G. Safety and tox-icological evaluation of Aflapin®: A novel Boswellia-derived anti-inflammatory product. Toxicology Mechanisms and Methods. 2010; 20: 556-563.
19. Sengupta K, Krishnaraju AV, Vishal AA, Mishra A, Golakoti T, Sarma KVS, Raychaudhuri SK, Raychaudhuri SP. Comparative Efficacy and Tolerability of 5-Loxin® and Aflapin® Against Osteoarthritis of the Knee: A Double Blind, Randomized, Pla-cebo Controlled Clinical Study. Int J Med Sci. 2010; 7(6):366-377.
20. Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, Moskowitz RW, Schnitzer TJ. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum 1995; 38:1541-1546.
21. Lequesne MG, Mery C, Samson M, Gerard P. Indexes of sever-ity for osteoarthritis of the hip and knee validation-value in comparison with other assessment tests. Scand J Rheumatology 1987; 65:85-89.
22. Bellamy N, Buchnan WW, Goldsmith CH, Campbell J, Stitt LW: Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to anti-rheumatic drug therapy in subjects with osteoarthritis of the hip or knee. J Rheumatol 1988, 15:1833-1840.
23. Chapman CR, Casey KL, Dubner R, Foley KM, Gracely RH, Reading AE: Pain measurement: an overview. Pain 1985, 22:1-31.
24. Bellamy N, Bell MJ, Goldsmith CH, Pericak D, Walker V, Raynauld JP, Torrance GW, Tugwell P, Polisson R: The effective-ness of hylan G-F 20 in subjects with knee osteoarthritis: an ap-plication of two sets of response criteria developed by the OARSI and one set developed by OMERACT-OARSI. Osteoar-thritis Cartilage 2005, 13:104-110.
25. Sengupta K, Krishnaraju AV, Satish AR, Mishra S, Golakoti T, Sarma KVS, Dey D, Raychaudhuri SP. A double blind, ran-domized, placebo controlled study of the efficacy and safety of 5-Loxin® for treatment of osteoarthritis of the knee. Arthritis Res Ther 2008; 10:R85.
26. Syrovets T, Buchele B, Krauss C, Laumonnier Y, Simmet T. Acetyl-boswellic acids inhibit lipopolysaccharide mediated TNF-alpha induction in monocytes by direct interaction with IkappaB kinases. J Immunol. 2005,174:498-506.
27. Gayathri B, Manjula N, Vinaykumar KS, Lakshmi BS, Balakrishnan A. Pure compound from Boswellia serrata extract ex-hibits anti-inflammatory property in human PBMCs and mouse macrophages through inhibition of TNFα, IL-1β, NO and MAP kinases. Int Immunopharmacol. 2007,7:473-482.
28. Roy S, Khanna S, Shah H, Rink C, Phillips C, Preuss HG, Subbaraju GV, Trimurtulu G, Krishnaraju AV, Bagchi M, Sen CK. Human genome screen to identify the genetic basis of the an-ti-inflammatory effects of Boswellia in micro vascular endothe-lial cells. DNA Cell Biol. 2005, 24:244-255.
29. Roy S, Khanna S, Krishnaraju AV, Subbaraju GV, Yasmin T, Bagchi D, Sen CK. Regulation of vascular responses to in-flammation: Inducible matrix metalloproteinase-3 expression in human microvascular endothelial cells is sensitive to an-ti-inflammatory Boswellia. Antioxid Redox Signal. 2006, 3:653-660.
30. Sengupta K, Golakoti T, Marasetti A, Tummala T, Ravada S, Krishnaraju A, Siba P Raychaudhuri SP. 30% 3-O-acetyl-11-keto-β-boswellic acid inhibits TNFα production and blocks MAPK/NFκB activation in lipopolysaccharide in-duced THP-1 human monocytes. J Food Lipids. 2009,16:325-344.
31. Kruger P, Daneshfar R, Eckert GP, Klein J, Volmer DA, Bahr U, Muller WE, Karas M, Schubert-Zsilavecz M, Abdel-Tawab M. Metabolism of Boswellic Acids in Vitro and in Vivo. Drug Metabol and Disposition. 2008, 36:1135-1142.
32. Kruger P, Kanzer J, Hummel J, Fricker G, Schubert-Zsilavecz M, Abdel-Tawab M. Permeation of Boswellia extract in the Caco-2 model and possible interactions of its constituents KBA and AKBA with OATP1B3 and MRP2. Eur J Pharm Sc. 2009,36:275-284.